General Information
Morpholino name: ang2 oligo1
Morpholino sequence: 5'-GCAGGCTGCCCATCCCAGGAAACC-3' Find in Genbank
Target name: angpt2
Target sequence: (Morpholino Target and ATG )Search in Genbank Search in Ensembl
AGTTTTTGATATATTTGTGAGTTTTCCGTCCCATCGGGCTCCTGCCATGTGGTGGGGTTGCTTGTTTCT
GGCAGCGCTGCTGGTGGTTGCAGATTGTGGAGGAGTTGAGCAGAAAACAGACGGACTCTGGAGCTCCACG
CCGAAATCCAACAGCAGCAGCGGTCGGAGGTATCACCGGATCCAGCATGGACAGTGCAGCTACACGTTTA
TCCTCCCGGAGAGCGATGGAAACACTTGTCGAGAGTTTAAATCGGGCACGGCGTACAATGCCAATGCATT
ACAGCGGGACGCTCCTCAACCCGAAGCCGACTTGTCCAACCAGAAGATCCAGCAGCTGGAGCACGTCATG
GAGAACTACACGCAGTGGCTACAGAAGATTGAGAACTACATCAAAGACAACATGAAGACGGAGATGGTGC
AGCTACAACAGAGCGCCGTCCACAACCACACGGCAGCCATGCTGGAAATGGGCACCAGTCTTCTGTCCCA
AACGGCAGAACAGACGCGAAAACTGACCGACGTGGAGACCCAGGTTTTGAATCAGACGTCGCGGTTGGAA
ATTCAGCTGCTGGAGAACTCGCTGTCCACCAATAAGCTGGAGAAGCAGCTCATGATACAGATCAATGAAA
TCAACAAGATTCATGACAAGAATGGGTTTCTGGAGGAGAAGATGCAGGAGCTGGAGGATCGGCACCGTCA
GGAGCTGGAGTCTCTGCGGACGGAGAAATCTGACCTGCAGGCTCTGGTCAGCAGACAGAGTTCAGTGATC
CGCGAGCTGGAGAATCAGCTGAGCAGAGCTACCGGAAACAGCACAGCACTTCAGAGACAGCAGCAGGACC
TGATGGAGAGCATGCGCAGCCTCCTCAGCCTCTGTGCTAAAGACGCCGCTACAGCAGTGGAACCGAACAG
CACCAAGCAGGCTGACGAGGAGCGAAAGTTTCGGGATTGTGCTGATCTTTATCAAGCAGGCTTCCAGAAA
AACGGAGTTTACACCATCAATATTAGCCCACAAGAGACCAAAAAGGTGTACTGTGTGATGGAGTCTGCTG
GCGGAGGCTGGACGGTGATCCAGAAGCGTGAAGACGGCACTGTGGATTTCCAGAAAACATGGAAAGAATA
TAAGATGGGTTTTGGAAGCGTGTCGGGCGAACACTGGCTGGGGAACGAGTTTGTCCACGTTCTGACCAAT
CAGAGGCAGCACGGCCTCCGCGTGGAGCTGAGTGACTGGGACGGACACCAGGCCTTTTCTCAGTACGACA
GCTTCCACATCGACAGCGAGAAACAGAAATACAGGTTGTTTTTGAAGACCCACAGCGGGACGGCGGGACG
GCAGAGCAGTTTGGCCGTTCATGGAGCAGACTTCAGCACCAAAGACGTGGATAATGATAACTGCACATGC
AAGTGTGCACTGATGCTCAGCGGCGGCTGGTGGTACGACGCCTGCGGGCCATCCAACCTGAACGGTGTGT
ATTACAGACAAGGACAGCATGTCGGAAAATTTAATGGAATCAAATGGCACTATTTCAAAGGGCCCAGTTA
CTCTCTGCGCTCCACCGTCATGATGATCCGAGGAGCCGACTTCTCATAGTCCTCT
Gene targeted: Find in ZFIN
Find in Pubmed All the morpholinos targets to the gene
Synonyms:
Comments:
Reference:
Survival Curve: Normality Curve:
ALL
Note: When more than one data point existed per dose an average was used. p53 morpholino co-injections were used to minimize non-specific toxicity effects (Robu et al. PLoS Genetics 2007)
Screens Performed (number of tests): Defects Observed:
None
Images
